TB-500 dosage: research quantities
The rat stroke experiment gives “more” an unexpectedly untidy answer. Its amounts describe that study; a human TB-500 dose remains unvalidated.
Stroke outcomes across tested amounts
In the Morris dose-response experiment, male Wistar rats with embolic stroke received full thymosin beta-4 at 2, 12 or 18 mg/kg by the intraperitoneal route. Neurological function improved at 2 and 12 mg/kg, with significant differences from day 14 through day 56. The 18 mg/kg group showed no significant benefit.
The authors proposed a modeled optimum of approximately 3.75 mg/kg. That value was an estimate from the animal results. I appreciate the refusal of this experiment to form a neat upward staircase: the largest amount did not deliver the clearest benefit. It makes a casual assumption that greater exposure produces greater repair especially hard to defend.
These figures describe full thymosin beta-4 in rats after a particular brain injury. They establish no safe or effective amount of the short fragment for a person.
Healthy-volunteer exposure
The intravenous Phase 1 study assigned 40 healthy volunteers to cohorts receiving full-length thymosin beta-4 at 42, 140, 420 or 1260 mg. The study included single and repeated administration and reported no serious adverse events or dose-limiting toxicity; other adverse events were infrequent and mild or moderate.
Those subjects were healthy and the substance was the full protein. The findings describe tolerability during that study, with no test of healing efficacy. I give the distinction more weight than the reassuring adjective “tolerated.” A short study in healthy volunteers leaves rare harm, long exposure and a different molecule unresolved.
TB-500 half-life
A half-life is the time required for an amount to fall by half. No validated human TB-500 half-life exists for the seven-amino-acid fragment. The full-protein safety and pharmacokinetic study reported dose-proportional exposure and a half-life that increased with dose; those observations concern intravenous thymosin beta-4.
Equine anti-doping work characterized TB-500 and its breakdown products for detection. A useful assay for horse samples answers a different question from the human distribution and clearance needed to support a dosing interval. Neither evidence stream establishes a human schedule for the fragment.
Unvalidated plans and uncertain contents
The thymosin beta-4 research overview provides the context for the animal and early human experiments. Plans circulated in peptide communities have no validation from controlled human TB-500 trials. Their apparent precision cannot supply the missing evidence.
Analytical work on misbranded and adulterated preparations adds an identity problem to the pharmacology problem. A stated amount cannot settle what a preparation contains. I distrust that apparent exactness when a dosage discussion fixes quantities while leaving the substance itself and human safety uncertain. The legal record adds a separate regulatory limit.